Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-23-013574
Filing Date
2023-03-24
Accepted
2023-03-24 07:01:20
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A ny20008229x2.htm DEFA14A 16565
2 ny20008229x2_nc1.jpg GRAPHIC 1839705
3 ny20008229x2_nc2.jpg GRAPHIC 1216527
  Complete submission text file 0001140361-23-013574.txt   3949668
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: DEFA14A | Act: 34 | File No.: 001-39398 | Film No.: 23757630
SIC: 2834 Pharmaceutical Preparations